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Abstract: 
There are few studies describing the extent to which low iron status affects osteoblastogenesis, 
despite evidence that iron deficiency produces adverse effects on bone density. The purpose of 
this study was to evaluate alterations in intracellular iron status by measuring iron-regulated gene 
and protein expression and to describe development of osteoblast phenotype in primary cells 
treated with iron chelator deferoxamine (DFOM) during differentiation. Using the well-described 
fetal rat calvaria model, cells were incubated with 0–8 µM DFOM throughout differentiation 
(confluence to day (D) 21), or only during early differentiation (confluence to D13–15) or late 
differentiation (D13–15 to D21). Changes in intracellular iron status were determined by 
measuring alterations in gene and protein expression of transferrin receptor and ferritin light 
chain and heavy chain. Development of osteoblast phenotype was monitored by measuring 
expression of genes that are known to be up-regulated during differentiation, analyzing the 
percentage of mineralized surface area, and counting the number of multi-layered bone nodules 
at the end of culture. Results indicate that treatment throughout differentiation with 8 µM DFOM 
alters iron-regulated genes and proteins by mid-differentiation (D13–15) in a pattern consistent 
with iron deficiency with concomitant down-regulation of osteoblast phenotype genes, especially 
osteocalcin. Additionally, alkaline phosphatase staining was lower and there was about 70% less 
mineralized surface area (p < 0.05) by D21 in wells treated throughout differentiation with 8 µM 
DFOM compared to control. Down-regulation of osteocalcin and alkaline phosphatase mRNA (p 
< 0.05) and suppressed mineralization (p < 0.05) was also evident at D21 in cells treated only 
during early differentiation. In contrast, treatment during late differentiation did not alter 
osteoblastic outcomes by D21. In conclusion, it appears that iron is required for normal 
osteoblast phenotype development, and that early rather than late differentiation events may be 
more sensitive to iron availability. 
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Introduction 
Iron deficiency is typically attributed to inadequate dietary intake, blood loss, or chronic 
inflammation [1] and is estimated to affect more than 2 billion people worldwide, particularly 
women and children [2]. Due to iron's indispensable role in numerous biochemical reactions, low 
body iron stores result in deleterious effects on the function of a number of biological 
systems [3]. 
Evidence from studies conducted in both humans and rats suggests that iron is necessary for 
balanced bone metabolism. Dietary iron intake appears to be associated with a protective effect 
on bone density in post-menopausal women [4], [5] and [6], while moderate to severe dietary 
iron deficiency in rats results in altered bone morphology and microarchitecture, decreased 
density and strength in femurs and vertebrae, and increased urinary bone turnover 
markers [7], [8], [9] and [10]. Research specifically examining the effects of iron deficiency on 
bone formation in vitro is limited. Naves Díaz et al [11] reported higher activity of alkaline 
phosphatase, a non-specific marker of osteoblastogenic potential [12], compared to control in 
MG-63 osteosarcoma cells after 48 and 96 h of treatment with deferoxamine (DFOM) or 
deferiprone. Conversely, Parelman et al [13] reported lower amounts of Alizarin red staining and 
increased transferrin receptor (TrfR) protein expression in hFOB 1.19 cells compared to control 
after acute exposure (48–96 h) to DFOM. There have been no studies specifically examining the 
influence of low iron availability on osteoblast maturation and function. 
Studies conducted in differentiating primary cells, rather than immortal cell lines, may be best 
suited to address questions related to iron deficiency induced changes in bone formation, since 
primary cells are believed to express osteoblast phenotype genes and produce extracellular 
matrix most similar to that of osteoblasts in vivo [14] and [15]. Therefore, in the present study, 
experiments were designed to generate low intracellular iron levels in primary cell cultures 
isolated from fetal rat calvaria, a well defined model of osteoblast differentiation which exhibits 
temporal regulation of osteoblast phenotype gene markers and culminates in nodules similar to 
woven bone [15]. Iron status was altered by treatment with DFOM, a membrane-permeable iron 
chelator shown to prevent iron uptake [16] and chelate iron from the intracellular iron pool [17]. 
Using this experimental model the effect of DFOM on iron-regulated genes and proteins and the 
extent to which low iron availability affects osteoblast phenotypic development and function 
could be evaluated. 
Materials and methods 
Animal care 
Female Sprague–Dawley rats were obtained on D13 of pregnancy (Harlan, SD, Raleigh, NC). 
Rats were housed at 19–20 °C with a 12 h light–dark cycle and had free access to Harlan 
Teklad 7002 6% mouse/rat diet and water. At D21 of pregnancy, dams were euthanized by 
CO2 overdose, pups were collected, and calvaria were aseptically removed [18]. All procedures 
were approved by the University of North Carolina at Greensboro Animal Care and Use 
Committee. 
Calvaria cultures 
Cells were enzymatically released from the calvaria in five sequential collagenase digestions as 
previously described [18]. Cells from the last four incubations were plated in separate T-75 
flasks and incubated 24 h in α-MEM (Invitrogen) containing 15% heat-inactivated fetal bovine 
serum (FBS) (Invitrogen) and 10% antibiotics. Antibiotics consisted of 1 mg/ml penicillin 
(Sigma), 0.5 mg/ml gentamicin (Invitrogen), and 2.5 µg/ml fungizone (Invitrogen). Cells from 
each flask were trypsinized, pooled, and seeded at 3000 cells/cm2 in 6 well plates. Cells were 
incubated up to 21 days at 37 °C with 5% CO2 in complete media containing α-MEM, 10% 
FBS, 10% antibiotics, 25 µg/ml ascorbic acid, 10 mM sodium β-glycerolphosphate, and 10− 8 M 
dexamethasone. Fresh media was provided every 2–3 days. DFOM (Sigma) was diluted to final 
concentrations in fresh media and delivered during media changes beginning at confluence 
(∼ D8) and either throughout the 2-week differentiation period, or only during the first or second 
week. Deionized water was the vehicle control (0 μM). 
Preliminary study 
A preliminary study was performed to establish the dose response relationship of DFOM and 
osteogenic outcomes in fetal rat calvaria cultures. Doses ranging from 0 to 32 µM DFOM were 
administered in fresh media at media changes throughout the differentiation period (confluence 
to D21). Samples were collected on D21 and percent mineralized surface area was analyzed (see 
below) along with gene expression of osteoblast phenotype markers using real-time PCR (see 
below). 
Real-time RT-PCR 
Cells were collected by scraping in 1 ml of TRIZOL (Invitrogen). Three separate wells were 
pooled per sample. RNA was extracted using procedures specified by the manufacturer and 
purity and concentrations were determined using NanoDrop Spectrophotometer ND-1000 
(NanoDrop Technologies, Inc.). Two micrograms of RNA was reverse transcribed using High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in the presence of 1 U/µl 
RNasin Ribonuclease Inhibitor (Promega). 
Fifty nanograms of cDNA was amplified using Taqman Fast Universal Mastermix and Taqman 
Gene Expression assays (Applied Biosystems) for rat. Osteoblast phenotype markers included 
alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteocalcin (OCN). Runx2, a key 
transcription factor involved in osteoblast differentiation, was also analyzed. Iron genes included 
TrfR, ferritin heavy chain (FerH), and ferritin light chain (FerL). Ribosomal protein, L32, was 
used as the endogenous control. Relative gene expression was quantified using the delta–delta Ct 
method. Genomic DNA contaminants contributed to less than 1% of the amplification signal in 
assays that used primers that were not designed around exon boundaries (L32, FerH, and FerL), 
and were therefore considered negligible. 
Western blotting 
Cells from 3 separate wells were lysed and pooled in cold RIPA buffer, containing 10 mM 
sodium fluoride, 20 mM β-glycerolphosphate, 0.1 mM sodium orthovanadate, and either 
protease inhibitor cocktail (Calbiochem) or 0.5 mM PMSF and 0.1 µg/µl aprotinin. Lysates were 
stored at − 80 °C until further analysis. Lysates were thawed and sonicated on ice, and 
centrifuged at 16,000 ×g for 20 min. Supernatants were removed and protein concentrations 
were determined with BCA assay by manufacturer's instructions (Pierce). 
Twenty micrograms of proteins per well was resolved on NuPage 4–12% bis–tris gels 
(Invitrogen). Proteins were transferred onto polyvinylidene difluoride membranes (Immobilon) 
and blocked in 5% (w/v) milk dissolved in Tris-buffered saline with 0.05% (v/v) Tween-20 
(TBS–T) (Sigma). Membranes were then incubated with primary antibodies overnight at 4 °C, 
washed in TBS–T, and incubated with secondary antibodies for 30 min at room temperature. 
Primary antibodies were diluted in 5% (w/v) bovine serum albumin (Sigma) in TBS–T and 
included mouse anti-β-actin (Sigma), mouse anti-transferrin receptor (Zymed), and rabbit anti-
ferritin (Abcam), which recognize both heavy and light subunits. HRP-conjugated secondary 
antibodies include donkey anti-mouse (Affinity BioReagents) and goat anti-rabbit (Cell 
Signaling). Signal was detected with Western Lightning Chemiluminescence Reagent Plus kit 
(PerkinElmer). Net intensity values of representative blots were determined with Kodak 1D 
Imaging Software (version 3.6.2) and normalized to net intensity of loading control, β-actin. 
Means are expressed as a percent of control. 
Staining 
These methods are described in detail elsewhere [19]. Briefly, cells were washed in PBS, fixed in 
10% neutral formalin buffer, and rinsed with deionized water. ALP-positive cells were stained 
using Naphthol AS MX-PO4 (Sigma) as substrate and Red Violet LB salt (Sigma) as coupler. 
Mineralized nodules were stained using the von Kossa method by incubating cells with 2.5% 
(w/v) silver nitrate (Fisher) solution for 30 min. Culture dishes were then rinsed in tap water and 
air dried overnight. 
Bone nodule quantification 
To assess osteoblast function, the percent mineralized surface area was analyzed semi-
quantitatively with Adobe Photoshop (version 6.0). Dishes of cells stained for alkaline 
phosphatase and von Kossa were scanned on a flatbed scanner at a resolution of 600 dpi. 
Identical, rectangular images of cell layers within each well were selected. All selections were 
taken from the same, central-most region of the well. Percent mineralized surface area was 
calculated by dividing the number of pixels corresponding to mineralized foci (von Kossa 
staining) by the total number of pixels in each image. Means are expressed as percent of control. 
Wells were also examined microscopically under a bright field illumination and mineralized and 
unmineralized nodules were counted (data not shown). This was used in conjunction to percent 
mineralized surface area analysis to verify that von Kossa staining was localized to mineralized, 
multi-layered nodules and to account for the presence of multi-layered, unmineralized nodules. 
Statistical analysis 
Data are expressed as mean ± SEM. Statistical differences were determined using one-way 
analysis of variance (ANOVA) with Tukey post hoc analysis. Univariate analysis was performed 
to check for interactions when there were two main effects of dose and time. For real-time PCR 
data, there was a significant interaction between the main effects of dose and time for all genes 
except FerH and FerL. Therefore, ANOVA was performed within each day followed by Tukey 
post hoc analysis for TrfR, OCN, BSP, ALP, and Runx2. Statistics were performed using SPSS 
version 16.0 for Windows (SPSS Inc., Chicago, IL, USA). A p-value less than 0.05 was 
considered significant. 
Results 
Preliminary study to determine DFOM dose 
Continuous exposure throughout differentiation to 8 µM and 32 µM DFOM, but not 0–4 µM 
DFOM, suppressed percent mineralized surface area (Fig. 1A). Since 8 µM DFOM was the 
lowest dose that produced significant suppression of mineralization and gene expression of 
osteoblast markers (Fig. 1B), this was the highest dose used in subsequent studies. 
 
 
Fig. 1. Dose response relationship of chronic DFOM treatment throughout differentiation and 
osteoblast differentiation outcomes. (A) Average percent mineralized surface area expressed as 
percent control (0 µM). Data represent mean ± SEM of 4 wells; ANOVA: p < 0.05. (B) Real-
time PCR analysis of osteoblast phenotype genes on D21. L32 was endogenous control and 
0 µM was calibrator sample. Data represent mean ± SEM of 4 determinations; 
ANOVA: p < 0.05. Treatments that are significantly different (p < 0.05) as determined by Tukey 
post hoc analysis are assigned different letters. Treatments that are not significantly different 
(p > 0.05) are assigned the same letters. 
Iron-regulated genes and proteins are altered by DFOM treatment 
Real-time PCR results show that TrfR gene expression was dose-dependently up-regulated by 
DFOM by mid-differentiation (∼ D15) and sustained until the end of culture (D21) (Fig. 2A). 
TrfR proteins were congruent with gene expression, with marked and sustained up-regulation 
from mid-differentiation to the end of culture (Fig. 2B). Real-time PCR analysis of FerL and 
FerH revealed that genes were slightly up-regulated by mid-differentiation and sustained until 
the end of culture (Fig. 2C). Conversely, ferritin proteins were markedly down-regulated at mid-
differentiation (Fig. 2D). 
 
Fig. 2. Iron-regulated genes and proteins in osteoblast-like cultures isolated from fetal rat 
calvaria and treated with 0–8 µM DFOM throughout differentiation. Mid and end represent 
samples taken at midpoint (∼ D15) and end of differentiation (D21), respectively. (A) Real-time 
PCR amplification of TrfR with L32 as endogenous control and 0 µM mid as calibrator sample. 
(B) Western blots of TrfR and loading control β-actin. Semi-quantitative net intensity values 
normalized to β-actin and expressed as percent control (mid 0 µM). (C) Real-time PCR 
amplification of FerH and FerL with L32 as endogenous control and mid 0 µM as calibrator 
sample. (D) Western blots of ferritin subunits and β-actin. Semi-quantitative net intensity values 
normalized to β-actin and expressed as percent control (mid 0 µM). PCR and semi-quantitative 
Western blotting data represent mean ± SEM of 4 determinations. For PCR, ANOVA: p < 0.05 
for all genes with respect to day, except FerH and FerL. Treatments that are significantly 
different (p < 0.05) as determined by Tukey post hoc analysis are assigned different letters. 
Treatments that are not significantly different (p > 0.05) are assigned the same letters. Similar 
results were observed in at least 2 independent studies. 
DFOM treatment suppresses mineralization and nodule development 
Representative wells of cells treated with 0–8 µM DFOM and co-stained for alkaline 
phosphatase and von Kossa are shown in Fig. 3A. Alkaline phosphatase staining was less intense 
and the nodules were markedly smaller in wells treated with 8 µM DFOM than in 0–4 µM 
treated wells. The percent mineralized surface area was approximately 70% lower after 
continuous 8 µM treatment with no significant difference among 0–4 µM groups (Fig. 3B). In 
8 µM DFOM treated wells the total number of nodules and the number of mineralized nodules 
per well were about 60% lower compared to control (p < 0.05, data not shown). The number of 
unmineralized nodules accounted for only about 20% of total nodules in control and was similar 
among all groups (p > 0.05, data not shown). Therefore, the differences in percent mineralization 
among treatments were primarily attributed to significantly lower numbers of mineralized 
nodules. 
 
Fig. 3. Osteoblast-like colonies in cultures of fetal rat calvaria treated with 0–8uM DFOM 
throughout differentiation (confluence–D21). (A) Representative wells of alkaline phosphatase-
positive colonies (pink) and mineralized bone nodules (black) on D21. (B) Average percent 
mineralized surface area. Data represent mean ± SEM of triplicate wells. ANOVA: p < 0.05; 
treatments that are significantly different (p < 0.05) as determined by Tukey post hoc analysis are 
assigned different letters. Treatments that are not significantly different (p > 0.05) are assigned 
the same letters. Similar results were observed in at least 2 independent studies. 
Osteoblast phenotype markers are down-regulated by DFOM treatment 
In fetal rat calvaria cultures, Runx2 is up-regulated the earliest, followed by ALP and BSP, and 
finally the most osteoblast-specific marker, OCN [15]. In the present study, gene expression in 
the control groups was generally consistent with typical up-regulation of osteoblast phenotype 
genes (Fig. 4). In contrast, all phenotype markers were dose-dependently down-regulated by 
mid-differentiation after treatment with 8 µM DFOM compared to control, and suppression was 
sustained until end of culture (Fig. 4). 
 
Fig. 4. Real-time PCR analysis of osteoblast phenotype genes and transcription factor Runx2 
from cultures isolated from fetal rat calvaria and treated with 0–8 µM DFOM throughout 
differentiation. Mid and end represent samples taken at midpoint (∼ D15) and end of 
differentiation (D21), respectively. L32 was the endogenous control and mid 0 µM was used as 
calibrator sample. Data represent mean ± SEM of 4 determinations. ANOVA: p < 0.05 with 
respect to day. Treatments that are significantly different (p < 0.05) as determined by Tukey post 
hoc analysis are assigned different letters. Treatments that are not significantly different 
(p > 0.05) are assigned the same letters. Similar results were observed in at least 2 independent 
studies. 
Iron-regulated genes and proteins, but not osteoblast phenotype parameters return to control 
levels after 8 µM DFOM treatment during early differentiation only 
Real-time PCR of TrfR gene expression revealed that treatment with 8 µM DFOM during early 
differentiation resulted in levels similar to control on D21, while treatment during late 
differentiation and continuous exposure to 8 µM DFOM resulted in up-regulation of TrfR 
(Fig. 5A). TrfR protein expression exhibited a trend that was generally congruent with genes 
(Fig. 5B). PCR analysis of ferritin genes revealed no marked alterations after DFOM treatment at 
any time point (Fig. 5C). In contrast, continuous treatment or treatment only during late 
differentiation resulted in down-regulation of proteins, while treating cells during early 
differentiation resulted in ferritin protein expression similar to control (Fig. 5D). 
 
Fig. 5. Iron-regulated genes and proteins in fetal rat calvaria cultures on D21 treated with 8 µM 
DFOM continuously or during early or late differentiation only. (A) Real-time PCR 
amplification of TrfR with L32 as endogenous control and 0 µM as calibrator sample. (B) 
Western blots of TrfR and loading control β-actin. Semi-quantitative net intensity values 
normalized to β-actin and expressed as percent control (0 µM). (C) Real-time PCR 
amplification of FerL and FerH with L32 as endogenous control and 0 µM as calibrator sample. 
(D) Western blots of ferritin and loading control β-actin. Semi-quantitative net intensity values 
normalized to β-actin and expressed as percent control (0 µM). Real-time PCR and Western 
blot data represent mean ± SEM of 4 determinations. For PCR, ANOVA: p < 0.05 for all genes, 
except FerL. Treatments that are significantly different (p < 0.05) as determined by Tukey post 
hoc analysis are assigned different letters. Treatments that are not significantly different 
(p > 0.05) are assigned the same letters. Similar results were observed in 2 independent studies. 
Representative wells of alkaline phosphatase and von Kossa stained osteoblast-like colonies in 
cultures treated with 8 µM DFOM continuously or during early or late differentiation only are 
shown in Fig. 6A. Alkaline phosphatase staining was less intense after continuous treatment with 
8 µM DFOM and the percent of mineralized surface area was significantly lower after both 
continuous and early treatment with 8 µM DFOM, a 72% (p < 0.05) and 40% (p < 0.05) 
decrease, respectively ( Fig. 6B). The percent mineralized surface area after late treatment was 
about 20% lower and was not significantly different from control (p > 0.05). Microscopic 
evaluation revealed that the total number of nodules was 70% lower (p < 0.05) and the number of 
mineralized nodules was 80% lower (p < 0.05) in wells treated continuously with 8 µM DFOM 
compared to controls (data not shown). Treatment during early or late differentiation resulted in 
about 30% lower mineralized nodules and total nodules per well for both groups, compared to 
control (p > 0.05, data not shown). The number of unmineralized nodules was similar among all 
groups (p > 0.05, data not shown). 
 
Fig. 6. Osteoblast-like colonies and osteoblast phenotype genes from fetal rat calvaria cultures 
on D21 treated with 8 µM DFOM continuously or during early or late differentiation only. (A) 
Representative wells of alkaline phosphatase-positive colonies (pink) and mineralized bone 
nodules (black) on D21. (B) Average percent mineralized surface area expressed as a percent of 
control (0 µM). Data represent mean ± SEM of triplicate wells. (C) Real-time PCR of osteoblast 
phenotype genes and transcription factor Runx2 with L32 as endogenous control and 0 µM as 
calibrator sample. Data represent mean ± SEM of four determinations. ANOVA: p < 0.05 for 
genes and percent mineralized surface area; treatments that are significantly different (p < 0.05) 
as determined by Tukey post hoc analysis are assigned different letters. Treatments that are not 
significantly different (p > 0.05) are assigned the same letters. Similar results were seen in at 
least 2 independent studies. 
Treating cells continuously during differentiation suppressed Runx2, ALP, BSP, and OCN at 
D21 compared to control (Fig. 6C). Treatment during early differentiation resulted in significant 
suppression of OCN and ALP (p < 0.05), but not Runx2 and BSP (p > 0.05) and a similar pattern 
of gene expression was seen after treatment during late differentiation only. 
Discussion 
These results demonstrate that chronic exposure of primary rat calvaria-derived osteoblasts to 
DFOM during differentiation suppresses osteoblast phenotypic development. Data also provide 
evidence that iron may be most critical during early differentiation. This study supports the 
hypothesis that iron deficiency-induced bone loss is the result of adverse effects on 
osteoblastogenesis. 
In the classical model of iron-mediated regulation of cellular iron status, low levels of 
intracellular iron typically prevent TrfR mRNA degradation while blocking ferritin translation in 
an attempt to increase intracellular iron concentration. In the current study, the cells responded to 
DFOM by up-regulating TrfR gene and protein expression, while simultaneously down-
regulating ferritin at the post-transcriptional level, suggesting that DFOM treatment lowered 
levels of intracellular iron. Furthermore, upon removal of DFOM, iron metabolism genes and 
proteins were restored to levels similar to control, suggesting dynamic alteration of iron-
regulatory genes and proteins that reflect changes in iron availability. Together, these data 
suggest that iron regulation in osteoblasts follows classic intracellular iron-mediated regulation. 
This hypothesis is further supported by previous studies in fetal rat calvaria cultures in which 
iron-regulated genes and proteins have been shown to be responsive to changes in increased iron 
concentrations [20]. However, iron metabolism in osteoblasts remains poorly understood and 
tissue-specific mechanisms may exist that utilize a combination of transcriptional and post-
translational modifications that ultimately determine final expression of iron uptake and storage 
proteins [21]. Also, ferritin expression in this culture system may not necessarily reflect an in 
vivo response to iron deficiency, since ascorbic acid, which is known to modulate ferritin 
metabolism [22], was present throughout the cell culture since it is required for the formation of 
nodules in fetal rat calvaria. 
In fetal rat calvaria cultures, nodules containing mature osteoblasts that express osteocalcin are 
thought to emerge from committed osteoprogenitors in a linear progression [15]. DFOM 
treatment appears to interrupt one or more pathways vital to this progression, but whether this 
results in a delay of differentiation or irreversible suppression is unknown. DFOM dose-
dependently down-regulated osteoblast gene markers after about one week of treatment. 
Similarly, DFOM resulted in suppression of mineralization, but in lower doses (2 and 4 µM), this 
suppression was mitigated so that percent mineralization resembled control at D21. Given the 
concomitant alterations in iron-regulatory genes and proteins, it appears that in standard 
differentiation media supplemented with low doses of DFOM, cells may compensate for 
decreased iron availability by altering expression of iron-metabolic proteins which results in 
outcomes that are favorable for supporting osteogenesis. 
In contrast, chronic exposure to 8 µM DFOM produced marked and sustained suppression of 
osteoblast phenotype genes and Runx2, alkaline phosphatase-positive colonies and percent 
mineralized surface area, as well as lower total number of nodules. Taken together, these data 
suggest that low iron availability may diminish osteoblastic phenotype in fetal rat calvaria by 
suppressing recruitment of cells into the osteoblast lineage. Additionally, prolonged DFOM 
exposure results in mineralized nodules that are markedly smaller than control, suggesting that 
the function of the recruited osteoblast-like cells in these colonies is also diminished. This 
sustained suppression of osteoblast phenotype and disrupted function occurred even though iron-
regulatory mechanisms attempted to compensate for the presence of the iron chelator, providing 
evidence that progression of osteoblast differentiation requires a critical concentration of iron. 
It appears that early differentiation events that are vital to progression from osteoprogenitor to 
osteoblast may be more dependent on iron availability than later events, and the suppression of 
phenotype after continuous treatment may be the result of sustained blockage of one or more 
early differentiation pathways. The suppression of osteoblast phenotype after treatment during 
early differentiation only was less severe than continuous treatment, suggesting that 
replenishment of iron to the media facilitates progression of differentiation that would otherwise 
be inhibited by continued exposure to 8 µM DFOM. The recovery of the cells lends credence to 
the hypothesis that iron-deficient conditions may induce a delay in osteoblast progression, 
however, it is not known whether extending the culture period past D21 would have resulted in 
complete recovery of osteoblast phenotype. 
Low intracellular iron is known to arrest the cell cycle, and in many cancer cells this is often 
followed by up-regulation of apoptotic processes [23]. In the osteoblastic MG-63 cell line, 
decreased proliferation has been reported after 48 h of treatment with DFOM in excess of 
10 µM [11]. In fetal rat calvaria, the primary proliferative phase occurs directly after plating and 
continues until confluence. This phase is reflected by high levels of DNA synthesis and cell 
cycle gene expression which fall to less than 20% of peak expression at 
confluence [14] and [24]. In the present study, all DFOM was administered after confluence, 
when differentiation is primarily characterized by matrix development, maturation, and 
mineralization [15]. Nonetheless, low levels of DNA synthesis have been shown to persist into 
early phases of differentiation when nascent nodules are multi-layering before gradually tapering 
off to negligible levels as differentiation progresses [24] and [25]. Therefore, the administration 
of DFOM may have had a suppressive effect on multi-layering potentially followed by 
promotion of pro-apoptotic pathways, which contributed to diminished osteoblastogenesis. 
Disrupted proliferation may also be a factor in the sustained suppression of osteoblast parameters 
observed after DFOM treatment during early differentiation rather than late differentiation, since 
later cultures would contain more post-mitotic osteoblasts. It should be noted that multi-layering 
occurs in concert with various external cues and intracellular signaling pathways, none of which 
are thought to be mutually exclusive, and are required for differentiation [14], [15] and [24]. This 
suggests that several mechanisms may contribute to iron deficiency's overall detrimental effects 
on osteoblast phenotype development during early differentiation. 
The accumulation of extracellular collagen matrix during early phases of fetal rat calvaria culture 
also contributes to the progression of osteoblast differentiation and mineralization [24] and [26]. 
Moreover, the extensive post-translational modification required to form mature type I collagen 
fibrils involves two iron-requiring enzymes, prolyl and lysyl hydroxylase [27]. Thus, low 
intracellular iron availability during early differentiation may result in production of immature 
collagen fibrils which cannot support osteoblast phenotype development and are not competent 
for mineralization. Parelman et al [13] reported no difference in type I collagen protein levels in 
hFOB 1.19 cells treated with 8 µM DFOM for 48 h compared to controls, but did not examine 
collagen maturation. 
Existing studies in multiple cell types have consistently shown that the effects of DFOM are 
reversed by simultaneously incubating cells with DFOM and an equimolar concentration of iron 
salts [e.g. [11], [28],[29] and [30]]. These studies, when taken alongside the iron-metabolic gene 
and protein data in the present study, suggest that incubating cells with DFOM results in 
outcomes that are specific to iron availability. 
These findings support existing evidence that iron deficiency produces bone loss via decreased 
osteoblastogenesis and provide insight into the mechanisms by which low iron may exert its 
effects. Although it appears that osteoblast differentiation may resume after iron is restored to 
adequate levels, even a transient interruption of bone formation may have long-term 
consequences in vivo, particularly since the two populations most vulnerable to iron deficiency 
anemia are children, who are still accruing bone mass, and women who will likely experience 
post-menopausal bone loss later in life. This study not only demonstrates an important role for 
iron in bone development, but underscores the need to develop effective prevention of iron 
deficiency anemia. 
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